Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators..

Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678.

2.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920.

PMID:
20584880
3.

Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators..

Circulation. 2014 Apr 22;129(16):e460-1. doi: 10.1161/CIRCULATIONAHA.113.008033. No abstract available.

4.
5.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
6.

Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease.

Choy-Shan A, Zinn A, Shah B, Danoff A, Donnino R, Schwartzbard AZ, Lorin JD, Grossi E, Sedlis SP.

Coron Artery Dis. 2012 Aug;23(5):354-8. doi: 10.1097/MCA.0b013e3283564897.

PMID:
22750913
7.
8.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679.

PMID:
24029780
9.

Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, Krone RJ, Sako EY, Rogers WJ, Garber AJ, King SB 3rd, Davidson CJ, Ikeno F, Frye RL; BARI 2D Study Group..

Circulation. 2012 Oct 23;126(17):2115-24. doi: 10.1161/CIRCULATIONAHA.112.092973.

10.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
11.

Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H.

J Clin Pharmacol. 2011 Feb;51(2):173-80. doi: 10.1177/0091270010368281.

PMID:
20484611
12.

[Rosiglitazone: no increase in cardiovascular mortality].

Jazet IM, Meinders AE.

Ned Tijdschr Geneeskd. 2009;153:A942. Dutch.

PMID:
19930745
13.

The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.

Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group..

Circulation. 2009 Dec 22;120(25):2529-40. doi: 10.1161/CIRCULATIONAHA.109.913111. Erratum in: Circulation. 2010 Mar 30;121(12):e254.

14.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
15.

Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Brooks MM, Chung SC, Helmy T, Hillegass WB, Escobedo J, Melsop KA, Massaro EM, McBane RD, Hyde P, Hlatky MA; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group..

Circulation. 2010 Oct 26;122(17):1690-9. doi: 10.1161/CIRCULATIONAHA.109.912642.

16.

Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.

Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, Escobedo J, Krishnaswami A, Slater J, Frye RL; BARI 2D Study Group..

J Am Coll Cardiol. 2013 Feb 19;61(7):702-11. doi: 10.1016/j.jacc.2012.11.036.

17.

[Revascularization in patients with type 2 diabetes and coronary artery disease: BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study Group].

Störk S, Ertl G, Nitschmann S.

Internist (Berl). 2010 May;51(5):674-6. doi: 10.1007/s00108-010-2593-6. German. No abstract available.

PMID:
20352177
18.

A randomized trial of therapies for type 2 diabetes and coronary artery disease.

BARI 2D Study Group., Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE.

N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796.

19.

Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK.

Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47. doi: 10.1002/pds.1722.

20.

Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients.

Contini GA, Nicolini F, Fortuna D, Pacini D, Gabbieri D, Vignali L, Valgimigli M, Manari A, Zussa C, Guastaroba P, De Palma R, Grilli R, Gherli T.

Int J Cardiol. 2013 Sep 30;168(2):1028-33. doi: 10.1016/j.ijcard.2012.10.030.

PMID:
23164591
Items per page

Supplemental Content

Support Center